Influence of Strontium on Bone Mineral Density and Bone Mineral Content Measurements by Dual X-Ray Absorptiometry

Nielsen, S. Pors; Slosman, Daniel O.; Sørensen, Ole; Basse-Cathalinat, B.; Cassin, P. De; Roux, Christian; Meunier, Pierre J.

doi:10.1016/s1094-6950(06)60402-2

Cited by 94 publications

(70 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Biopsy studies suggest that the average bone strontium content after 2 years of treatment is around 1% [13]. A bone strontium content of 1% causes a 10% increase in BMD [14] which would be consistent with the 9% increase in BMD observed in the bisphosphonate-naive group in this study. The blunted BMD response observed in the prior bisphosphonate group is therefore likely to result from reduced strontium uptake in to the bone due to a reduced number of new bone packets caused by the prolonged suppression of bone turnover following bisphosphonate therapy [4].…”

Section: Discussionsupporting

confidence: 88%

The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years

et al. 2011

View full text Add to dashboard Cite

show abstract

“…As strontium has a higher atomic number than calcium, it attenuates more X-rays than calcium does. This attenuation can result in an overestimation of BMD that requires an adjustment for bone strontium content (58).…”

Section: Strontium Ranelatementioning

confidence: 99%

An overview on the treatment of postmenopausal osteoporosis

Maeda

Lazaretti-Castro

2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Osteoporosis is a worldwide health problem related to the aging of the population, and it is often underdiagnosed and undertreated. It is related to substantial morbidity, mortality and impairment of the quality of life. Estrogen deficiency is the major contributing factor to bone loss after menopause. The lifetime fracture risk at 50 years of age is about 50% in women. The aim of the treatment of osteoporosis is to prevent fractures. Non-pharmacological treatment involves a healthy diet, prevention of falls, and physical exercise programs. Pharmacological treatment includes calcium, vitamin D, and active medication for bone tissue such, as anti-resorptives (i.e., SERMs, hormonal replacement therapy, bisphosphonates, denosumab), bone formers (teriparatide), and mixed agents (strontium ranelate). Bisphosphonates (alendronate, risedronate, ibandronate, and zoledronate) are the most used anti--resorptive agents for the treatment of osteoporosis. Poor compliance, drug intolerance, and adverse effects can limit the benefits of the treatment. Based on the knowledge on bone cells signaling, novel drugs were developed and are being assessed in clinical trials. Arq Bras Endocrinol Metab. 2014;58(2):162-71 Keywords Osteoporosis; treatment, post-menopause; anti-reabsorptives RESUMO A osteoporose é um problema de saúde mundial relacionada com o envelhecimento da população e muitas vezes é subdiagnosticada e subtratada. Relaciona-se à significativa morbidade, mortalidade e redução da qualidade de vida. A deficiência de estrogênio é o principal fator que contribui para a perda óssea após a menopausa. O risco de fratura a partir dos 50 anos de idade é de cerca de 50% em mulheres. O objetivo do tratamento da osteoporose é a prevenção de fraturas. O tratamento não farmacológico envolve uma dieta saudável, prevenção de quedas e de programas de exercícios físicos. O tratamento farmacológico inclui cálcio, vitamina D e medicação ativa em tecido ósseo, tais como antirreabsortivos (SERMs, terapia de substituição hormonal, bifosfonatos, denosumabe), formadores de osso (PTH e análogos) e agentes mistos (ranelato de estrôncio). Os bisfosfonatos (alendronato, risedronato, ibandronato e zoledronato) são os mais utilizados agentes antirreabsortivos para o tratamento da osteoporose. A baixa aderência, a intolerância medicamentosa e os efeitos adversos podem limitar os benefícios do tratamento. Com base no conhecimento da sinalização entre as célu-las ósseas, novos medicamentos foram desenvolvidos e estão sendo avaliados em ensaios clínicos.Arq Bras Endocrinol Metab. 2014;58(2):162-71

show abstract

“…Although a commendable effort was made in the SOTI trial to correct the BMD data for the atomic number effect of strontium, there is clearly a considerable uncertainty about the accuracy of the corrections that have been done. 21,23 Furthermore a strong relationship between the increase in BMD and a subsequent reduction of a new vertebral or hip fracture risk has been demonstrated in SR-treated patients, indicating that BMD level monitoring may be valuable in these patients. After treatment withdrawal, patients who switched to a placebo after four years experienced a significant reduction in BMD, showing how SR effects had been progressively reversible and reflecting the clearance of strontium from the bone.…”

Section: Bone Mineral Densitymentioning

confidence: 99%

Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal

Cesareo¹,

Napolitano²,

Iozzino³

2009

IJWH

View full text Add to dashboard Cite

Influence of Strontium on Bone Mineral Density and Bone Mineral Content Measurements by Dual X-Ray Absorptiometry

Cited by 94 publications

References 9 publications

The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years

The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years

An overview on the treatment of postmenopausal osteoporosis

Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal

Contact Info

Product

Resources

About